PI Major Mutations: None PI Accessory Mutations: None

PR Other Mutations: R41K ::: - L63P ::: - E65D ::: - K70R ::: - 172lV :::: - V77l ::: - 193L ::: - 193L ::: - 172lV ::: -

#### Protease Inhibitors

Susceptible darunavir/r (DRV/r) Susceptible fosamprenavir/r (FPV/r) Susceptible indinavir/r (IDV/r) Susceptible lopinavir/r (LPV/r) Susceptible nelfinavir (NFV) Susceptible saguinavir/r (SQV/r) Susceptible tipranavir/r (TPV/r) Susceptible

Mutation scoring: PR

atazanavir/r (ATV/r)

HIVDB 9.5.1 (2023-11-05)

HIVDB 9.5.1 (2023-11-05)

No drug resistance mutations were found for PI.

Drug resistance interpretation: RT

M1841 175 NRTI Mutations:

NNRTI Mutations: K103N ---

RT Other Mutations:

Nucleoside Reverse Transcriptase Inhibitors abacavir (ABC) Low-Level Resistance

zidovudine (AZT) Susceptible stavudine (D4T) Susceptible didanosine (DDI) Potential Low-Level Resistance emtricitabine (FTC) High-Level Resistance

lamivudine (3TC) High-Level Resistance tenofovir (TDF) Susceptible

Non-nucleoside Reverse Transcriptase Inhibitors

doravirine (DOR) Susceptible High-Level Resistance efavirenz (EFV) etravirine (ETR) Susceptible nevirapine (NVP) High-Level Resistance rilpivirine (RPV) Susceptible

#### RT comments

## NRTI

• M184V/I cause high-level in vitro resistance to 3TC and Iow/intermediate resistance to ABC (3-fold reduced susceptibility). M184V/I are not contraindications to continued treatment with 3TC or FTC because they increase susceptibility to AZT and TDF and are associated with clinically significant reductions in HIV-1 replication.

#### NNRTI


K103N is a non-polymorphic mutation that confers high-level reductions in NVP and EFV susceptibility. It is the most commonly transmitted DRM.


# Other

- . V90I is a polymorphic accessory mutation weakly selected by each of the NNRTIs. It is associated with minimal, if any, detectable reduction in NNRTI susceptibility.
- K101Q is a relatively non-polymorphic mutation that is weakly selected in persons receiving NVP and EFV. It is of uncertain phenotypic and clinical significance.
- V179I is a polymorphic mutation that is frequently selected in persons receiving ETR and RPV. However, it has little, if any, direct effect on NNRTI susceptibility.

Mutation scoring: RT

HIVDB 9.5.1 (2023-11-05)





## Drug resistance interpretation: IN

HIVDB 9.5.1 (2023-11-05)

None INSTI Major Mutations: INSTI Accessory Mutations: None

IN Other Mutations: \$17N - 1721V - 1124 - 1124 - 1258 - 1268 - 1

## Integrase Strand Transfer Inhibitors

bictegravir (BIC) Susceptible cabotegravir (CAB) Susceptible dolutegravir (DTG) Susceptible elvitegravir (EVG) Susceptible Susceptible raltegravir (RAL)

No drug resistance mutations were found for INSTI.

Mutation scoring: IN

HIVDB 9.5.1 (2023-11-05)